Montemagno et al. (2023) demonstrated that novel VEGF splice variants in renal cell carcinoma are less effectively inhibited by conventional anti-VEGF/VEGFR therapies, suggesting that these variants may serve as alternative therapeutic targets for patients resistant to current treatments. Here, VEGFA is linked to renal cell carcinoma.